Navigation Links
Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Date:10/8/2007

LAUSANNE, Switzerland, October 8 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented Professors Minoru Toyota and Keiichi Nakayama with the 2007 JCA-Mauvernay Award for their outstanding oncology research work. The Awards were presented during the General Assembly of the 66th Annual Conference of the JCA in Yokohama, Japan, by Professor Setsuo Hirohashi, President of the Japanese Cancer Association (JCA) and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group.

The work of Professor Toyota from the First Department of Internal Medicine, Sapporo Medical University, focuses on "DNA methylation as a new target for therapy in cancer". His applied research may lead to novel strategies for developing molecular markers and cancer therapies. DNA methylation of genes could be a useful molecular marker to predict response to chemotherapeutic drugs. The basic research work conducted by Professor Nakayama from the Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, focuses on "Ubiquitin ligases involved in cell-cycle control and cancer". His work shows that deregulation of the proteolytic system might result in uncontrolled proliferation, genomic instability and cancer. A better understanding of the ubiquitylation machinery will provide new insights into the regulatory biology of cell-cycle transitions and the development of anti-cancer drugs.

"Our goal with this Award is to recognise and reward excellent research conducted by Japanese scientists and to give them the opportunity to show their work to fellow researchers," said Kamel Besseghir, CEO of Debiopharm S.A. "This may increase the chances of their discoveries leading to the development of new medicines."

In its third year, the JCA-Mauvernay Award is organised jointly by the JCA and Debiopharm to honour innovative fundamenta
'/>"/>

SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Japanese delegates highlight Wisconsin at BIO Chicago
2. Japanese telecom opens liason office at UW-Platteville
3. Promega, Japanese lab announce partnership
4. Japanese institute installs Imago system
5. Sonic Foundry makes Japanese version of lead product
6. OpGen forges agreement with Japanese importer
7. Japanese biotech is booming and linked with Midwest
8. Japanese institute will develop for UWs Croquet platform
9. 40 Midwest biotech organizations to explore Japanese partnerships
10. Japanese Continue Relentless Biotech Stake in Midwest
11. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 When a leading manufacturer ... request to design an industrial oven ... medications being produced using a 3D-printing process, Gruenberg ... robotic gantry, heat-saving windows, and internal actuators and ... 3D-printed pills to exact specifications. , To ensure ...
(Date:5/29/2015)... RESEARCH TRIANGLE PARK, N.C. , May 29, 2015 /PRNewswire/ ... that Roger Jeffs , Ph.D., President and Co-Chief Executive ... on the company,s business at the Jefferies 2015 Global Healthcare ... The presentation and the immediately following Q&A session will ... Eastern Time, and can be accessed via a live webcast ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ... Companies"  to their offering.       ... a challenge in management. With nearly 8 ... seven major markets of the world and ...
(Date:5/28/2015)... , May 27, 2015 Research ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
Breaking Biology Technology:New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3
... N.Y. , July 29 On ... Publication Professionals (ISMPP) and the Medical Publishing Insights and ... various MPIP initiatives ( http://www.mpip-initiative.org ). The web page ... MPIP initiative, updating viewers on new or planned activities, ...
... , Saliva-Based DNA Collection Product Chosen for Study to Identify ... , , ... /PRNewswire/ - DNA Genotek, a leading provider of products ... the world,s leading TB vaccine research site, the South African ...
... , VANCOUVER , July 28 ... ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) ... trial of MultiStem(R), its allogeneic cell therapy product, ... more commonly referred to as a heart attack. ...
Cached Biology Technology:ISMPP and MPIP Announce New Medical Publishing Website 2ISMPP and MPIP Announce New Medical Publishing Website 3DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 2DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... NEW YORK , May 19, 2015  Technology ... resources both internally and in the cloud. Passwords and ... the use of OTP and standards-based specifications such as ... that the outmoded use of passwords presents for BYOD, ... needs a unified biometric identity protocol. ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
... Goldfarb LLP is investigating whether the board of ... shareholder protection laws as evidenced through alleged inconsistencies in ... stock before June 15, 2012 are encouraged to contact ... about their rights and remedies. "On ...
... Athens, Ga. University of Georgia scientists have discovered ... the immune system. Kimberly Klonowski, assistant professor of cellular ... Sciences, and her colleagues found that administering a cell-signaling ... reduces their peak viral load by nearly three times. ...
... Research Centre of Finland in collaboration with the University ... signature which predicts progression to Alzheimer,s disease months or ... occur. The goal of the new collaboration between VTT ... a large patient cohort as well as to discover ...
Cached Biology News:UGA study reveals flu-fighting role for well-known immune component 2VTT and GE Healthcare developing novel biomarkers to predict Alzheimer's disease 2